Warner Chilcott Plc (NASDAQ: WCRX) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Warner Chilcott Plc and Eyegate Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Warner Chilcott Plc N/A N/A N/A
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Warner Chilcott Plc and Eyegate Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warner Chilcott Plc 0 0 0 0 N/A
Eyegate Pharmaceuticals 0 0 4 0 3.00

Institutional & Insider Ownership

13.0% of Eyegate Pharmaceuticals shares are held by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Warner Chilcott Plc and Eyegate Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Warner Chilcott Plc N/A N/A N/A N/A N/A
Eyegate Pharmaceuticals $670,000.00 29.27 -$13.34 million ($1.30) -0.88

Warner Chilcott Plc has higher revenue, but lower earnings than Eyegate Pharmaceuticals.

Summary

Eyegate Pharmaceuticals beats Warner Chilcott Plc on 4 of the 7 factors compared between the two stocks.

Warner Chilcott Plc Company Profile

Warner Chilcott Public Limited Company is a specialty pharmaceutical company. The Company is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. The Company’s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product, launched in January 2011, that offers women the lowest dosage of estrogen of any oral contraceptive available in the United States market. In October 2013, Actavis Inc acquired the entire share capital of Warner Chilcott PLC.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Receive News & Ratings for Warner Chilcott Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Warner Chilcott Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.